Eight patients with refractory multiple myeloma were treated with clofarabine 4 mg/m2/day on days 1-5 of a 28 day cycle. No objective evidence of anti-myeloma activity was observed (median time to progression of 52 days). All patients experienced grade 3-4 neutropenia and a greater than 50% decrease in platelet counts during treatment.